Publications scientifiques sur les diagnostics non invasifs BioPredictive

Études évaluées par les pairs validant les diagnostics sanguins BioPredictive pour les maladies du foie — des cohortes pionnières aux méta-analyses à long terme.

117/435 Résultats pour
“type 2 diabetes”

“type 2 diabetes” Tout effacer
  1. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Score 100

    …Consecutive patients with type 1 or 2 diabetes had clinical, biological parameters…

    FibroTest Metabolic

  2. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Score 100

    Type 2 diabetes. ### Methods A total of 179 people with Type 2

    FibroTest NashTest Metabolic

  3. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Score 100

    type-2-diabetes in comparison with patients without type-2-diabetes. These…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  4. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Score 99

    …with the pandemic of type 2 diabetes. Here, the authors aimed to…

    ActiTest FibroTest NashTest-2 Metabolic

  5. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.

    Petit JM et al. · Liver Int · 2011 Score 99

    …in unselected patients with type 2 diabetes. ### Design, Setting And Participants Two…

    FibroTest Metabolic

  6. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts. Key publication

    Denimal D et al. · Cardiovasc Diabetol · 2024 Score 98

    …risk in individuals with type 2 diabetes (T2D). The primary objective of…

    ActiTest FibroTest NashTest SteatoTest +1

  7. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

    Bril F et al. · J Investig Med · 2019 Score 98

    …panels in patients with type 2 diabetes mellitus (T2DM). All patients underwent…

    ActiTest FibroTest NashTest SteatoTest +1

  8. Glycogenic hepatopathy. Review

    Khoury J et al. · Hepatobiliary Pancreat Dis Int · 2018 Score 98

    …associated with uncontrolled diabetes mellitus, most commonly type 1, expressed as right…

    FibroTest Metabolic

  9. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Score 97

    …In type-2 diabetes, FibroTest predicted cardiovascular events and improved the Framingham…

    FibroTest SteatoTest Metabolic

  10. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Score 97

    …Endocrinologists and those caring for patients with type 2 diabetes mellitus (T2DM…

    FibroTest Metabolic

  11. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

    Bril F et al. · Diabetes Care · 2020 Score 96

    …assessed in patients with type 2 diabetes mellitus (T2DM). ### Research Design And…

    FibroTest NashTest-2 Metabolic

  12. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study. Key publication

    Denimal D et al. · Cardiovasc Diabetol · 2025 Score 96

    …calcification in individuals with type 2 diabetes (T2D) remains unclear. This study…

    ActiTest FibroTest NashTest SteatoTest +1

  13. Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

    Caussy C et al. · Diabetes Care · 2025 Score 95

    …study including participants with type 2 diabetes and/or obesity and MASLD…

    FibroTest Metabolic

  14. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Score 95

    ### Background One of the unmet needs in patients with type 2 diabetes

    FibroTest NashTest-2 SteatoTest Metabolic

  15. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

    Jacqueminet S et al. · Clin Gastroenterol Hepatol · 2008 Score 95

    …In the population with type 2 diabetes who were 45 years or…

    FibroTest SteatoTest Metabolic

  16. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Score 94

    …LVDD) in patients with type 2 diabetes mellitus (T2DM). **Methods**: This single…

    FibroTest Metabolic

  17. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Score 94

    …be less accurate in type 2 diabetes mellitus (T2DM). We aimed to…

    FibroTest Metabolic

  18. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Score 93

    Type-2 diabetes provides an interesting model for assessing liver steatosis. Clinico…

    SteatoTest Metabolic

  19. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Score 93

    FibroTest SteatoTest Metabolic

  20. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Score 92

    …tests in patients with type 2 diabetes (T2D) using the intention-to…

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  21. Screening studies of transient elastography and FibroTest in the general population - Authors' reply.

    Ginès P et al. · Lancet Gastroenterol Hepatol · 2017 Score 92

    FibroTest Other

  22. Screening studies of transient elastography and FibroTest in the general population.

    Poynard T et al. · Lancet Gastroenterol Hepatol · 2017 Score 92

    FibroTest Other

  23. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Score 91

    …hazardous alcohol use, or type 2 diabetes, reported higher prevalence of advanced…

    FibroTest Other

  24. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.

    Petroff D et al. · Dig Liver Dis · 2018 Score 91

    FibroTest Metabolic

  25. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication

    Deckmyn O et al. · Biomedicines · 2022 Score 90

    …or without type 2 diabetes mellitus (T2DM), alpha-2 macroglobulin (A2M), apolipoprotein…

    FibroTest Metabolic

  26. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Score 90

    …Americans [odds ratio (OR)(adj)=2.08; 95% confidence interval (CI),0…

    ActiTest FibroTest HCV

  27. Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

    White DL et al. · Dig Dis Sci · 2012 Score 89

    …White male methadone-users had 2.1-fold excess advanced inflammation risk…

    ActiTest FibroTest HCV

  28. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Score 89

    2% had hypertransaminasemia. The percent of patients with overweight, obesity, diabetes, hypertension…

    ActiTest FibroTest NashTest SteatoTest +1

  29. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Score 89

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…

    SteatoTest Metabolic

  30. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Review

    Vilar-Gomez E et al. · J Hepatol · 2018 Score 88

    The correct identification of patients at increased risk of non-alcoholic steatohepatitis…

    FibroTest Metabolic

  31. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.

    Montaudié H et al. · J Eur Acad Dermatol Venereol · 2011 Score 88

    Type 2 diabetes and obesity, were associated with a significant increased risk…

    FibroTest Other

  32. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Score 87

    2.3±1.8; 3±2.6 and 3.8±2.7…

    FibroTest SteatoTest HBV HCV +1

  33. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.

    White DL et al. · Hepatology · 2012 Score 87

    …1.86-6.54 versus OR(adjusted advanced inflammatory activity) = 2.23…

    ActiTest FibroTest HCV

  34. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.

    Khalaf N et al. · Clin Gastroenterol Hepatol · 2015 Score 86

    …their caffeine from coffee (50.2% vs. 43.0%; P = .035). Hepatoprotective…

    FibroTest HCV

  35. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Score 86

    ActiTest AshTest FibroTest NashTest +6

  36. An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

    Poynard T et al. · Biomedicines · 2025 Score 86

    …cohort, 286 outpatients with type 2 diabetes, and in six previously published…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  37. Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2023 Score 85

    FibroTest Metabolic

  38. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Score 85

    …elderly patients without liver disease (group A, 85.2+/-7.3 years…

    FibroTest Metabolic

  39. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.

    Bauer B et al. · JAMA Dermatol · 2017 Score 84

    ### Importance The long-term implications of hepatotoxic effects in patients with psoriasis…

    FibroTest NashTest Other

  40. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Key publication

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Score 84

    ### Background Although the FibroTest has been validated as a biomarker to determine…

    FibroTest Alcohol HBV HCV +1

  41. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Score 83

    ### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…

    FibroTest NashTest SteatoTest Metabolic

  42. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.

    Ratziu V et al. · Aliment Pharmacol Ther · 2007 Score 83

    …prevalence - the highest being for type 2 diabetics: advanced steatosis 66%, NASH…

    FibroTest NashTest SteatoTest Metabolic

  43. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Score 83

    …mortality (Hazard ratio [95% CI]: 2.75 [1.26; 6.03]) than…

    FibroTest NashTest SteatoTest Metabolic

  44. Noninvasive Assessment of Liver Fibrosis. Key publication Review

    Castera L et al. · N Engl J Med · 2025 Score 82

    FibroTest Metabolic

  45. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication

    Poynard T et al. · Diagnostics (Basel) · 2025 Score 82

    **Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…

    FibroTest-T2D Metabolic

  46. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Score 81

    …kg/m^2^. Concomitantly, significant improvements in triglycerides, ALT, diabetes markers and…

    FibroTest NashTest SteatoTest Metabolic

  47. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Score 81

    …52.5% with F4 NASH, 40% male, 72% with type 2 diabetes

    FibroTest Metabolic

  48. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Score 80

    …The performance of the SteatoTest-2 was compared with the reference test…

    NashTest-2 SteatoTest-2 Metabolic

  49. Silymarin in non alcoholic fatty liver disease.

    Cacciapuoti F et al. · World J Hepatol · 2013 Score 80

    ### Aim This study was undertaken to evaluate the hepatic effects of silybum…

    SteatoTest Metabolic

  50. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.

    Zelber-Sagi S et al. · Hepatology · 2008 Score 80

    ### Unlabelled Physical activity (PA) is commonly recommended for nonalchoholic fatty liver disease…

    SteatoTest Metabolic

  51. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Score 79

    ### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…

    ActiTest FibroTest SteatoTest Metabolic

  52. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Score 79

    …Most subjects (84.2%) with FLI < 60 had S0 and none had…

    SteatoTest Metabolic

  53. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Score 78

    In the current era of therapy with direct-acting antiviral (DAAs) drugs…

    FibroTest HCV

  54. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Score 78

    ### Background Blood tests of liver injury are less well validated in non…

    ActiTest FibroTest SteatoTest Metabolic

  55. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Score 77

    ### Background One of the unmet needs in patients with metabolic risks is…

    FibroTest NashTest SteatoTest Metabolic

  56. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. Key publication

    Poynard T et al. · JHEP Rep · 2021 Score 77

    …3, alcohol consumption, and type 2 diabetes mellitus. ### Conclusions The results showed…

    LCR1 LCR2 HCV

  57. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Score 77

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  58. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Score 76

    …08 for simple steatosis, and 2.80 and 0.18 for NASH…

    NashTest SteatoTest Metabolic

  59. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. Key publication

    Poynard T et al. · Gastro Hep Adv · 2022 Score 76

    …status, alcohol consumption, and type-2 diabetes. LCR1-LCR2 outperformed PAGE-B…

    FibroTest LCR1 LCR2 HBV

  60. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Score 75

    …if abnormalities in at least 2 tests (serial PIIINP, TE, or FibroTest…

    FibroTest Other

  61. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Score 75

    …The prevalence of presumed fibrosis was 2.8%, (209/7,463), including…

    FibroTest Alcohol HBV HCV +3

  62. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Score 74

    …aspartate aminotransferase/alanine aminotransferase ratio, diabetes score (BARD score), FibroMeter, FibroTest, enhanced…

    FibroTest Metabolic

  63. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Score 74

    ### Background No blood test has been shown to be effective in the…

    LCR1 LCR2 Alcohol HBV +4

  64. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

    Thabut D et al. · Am J Gastroenterol · 2006 Score 74

    …Among the 2,169 patients who underwent liver biopsy, bridging fibrosis (F2…

    FibroTest HCV

  65. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010 Score 73

    …mass index >28 kg/m(2) and high alcohol consumption. Neither long…

    FibroTest Other

  66. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.

    Berends MA et al. · Liver Int · 2007 Score 73

    ### Background Methotrexate (MTX) use is associated with hepatic fibrosis in psoriasis patients…

    FibroTest Other

  67. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.

    Coco B et al. · J Viral Hepat · 2007 Score 72

    …their sensitivities were 85.2%/78.3%; specificities 90.7%/98.2

    FibroTest Alcohol HBV HCV +1

  68. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

    Bedossa P et al. · Hepatology · 2012 Score 72

    …had A ≥ 2, whereas no patients with A < 2 had NASH. This…

    Metabolic

  69. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Review

    Festi D et al. · Aliment Pharmacol Ther · 2013 Score 71

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  70. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Score 71

    …Complicated syndromes often accompanied by obesity and diabetes makes no standard treatment…

    ActiTest FibroTest SteatoTest Metabolic

  71. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Score 71

    …When the 2 groups were pooled together a FT cutoff of 0…

    FibroTest Metabolic

  72. Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.

    Crisan D et al. · Indian J Med Res · 2017 Score 70

    ### Background & Objectives One of the multiple factors contributing to virological response in…

    ActiTest FibroTest SteatoTest HCV

  73. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Score 70

    ### Background Liver biopsy is considered the gold standard for assessing histologic lesions…

    NashTest Metabolic

  74. The non-invasive assessment of hepatic fibrosis. Review

    Gheorghe G et al. · J Formos Med Assoc · 2021 Score 69

    type methods for the evaluation of hepatic fibrosis; usually, there are 2

    ActiTest FibroTest Alcohol HBV +2

  75. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication Meta Analysis

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Score 69

    FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…

    FibroTest Alcohol HBV HCV +2

  76. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Score 68

    ### Background And Objective Obstructive sleep apnoea (OSA) could be an independent risk…

    NashTest SteatoTest Metabolic

  77. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Score 68

    FibroTest Other

  78. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Score 68

    …This resulted in twice as many cases of cirrhosis being detected, 2

    ActiTest FibroTest Alcohol HBV +3

  79. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Score 67

    …dB m(-1) for S ≥ 2, and 296 dB m(-1) for…

    SteatoTest Metabolic

  80. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

    Steininger K et al. · J Viral Hepat · 2017 Score 67

    Acute hepatitis C virus infection remains a major health concern in human…

    FibroTest HCV HIV

  81. FibroMAX: towards a new universal biomarker of liver disease? Review

    Morra R et al. · Expert Rev Mol Diagn · 2007 Score 66

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  82. Noninvasive evaluation of NAFLD. Review

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Score 66

    A common clinical concern in patients with NAFLD is whether they have…

    ActiTest FibroTest NashTest SteatoTest +1

  83. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Score 65

    ### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…

    FibroTest Metabolic

  84. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

    Sebastiani G et al. · World J Gastroenterol · 2007 Score 65

    …diagnose significant fibrosis (F > or = 2 by METAVIR) and cirrhosis (F4 by…

    FibroTest HBV

  85. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Score 65

    ### Background And Aim One of the unmet needs in subjects with metabolic…

    ActiTest FibroTest NashTest NashTest-2 +3

  86. Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.

    Maisonnasse P et al. · Gastro Hep Adv · 2022 Score 64

    …Similar kinetics of apolipoprotein A1, HP, and alpha-2-macroglobulin were observed…

    FibroTest Other

  87. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Score 64

    …male gender (Relative Risk=3.29), HIV co-infection (2.33), and…

    FibroTest Alcohol HBV HCV +1

  88. Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease. Key publication

    Peta V et al. · Clin Res Hepatol Gastroenterol · 2020 Score 63

    …HCC in patients without cirrhosis; (2) could increase the performance of standard…

    ActiTest FibroTest Alcohol HBV +2

  89. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Key publication

    Poynard T et al. · Clin Chem · 2004 Score 63

    …Discordance was attributable to failure of markers in 13 patients (2.4…

    ActiTest FibroTest HCV

  90. Noninvasive diagnosis in alcohol-related liver disease.

    Hadefi A et al. · Health Sci Rep · 2020 Score 62

    ### Background Alcohol-related liver disease (ALD) represents a major cause of death…

    FibroTest Alcohol

  91. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection

    · 2015 Score 62

    …and entecavir in children aged 2–11 years) for first- and second…

    FibroTest HBV

  92. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.

    Alric L et al. · Transpl Int · 2009 Score 62

    To assess the accuracy of the noninvasive tools, fibrotest (FT) and liver…

    FibroTest HBV HCV

  93. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

    El-Shabrawi MH et al. · Eur J Gastroenterol Hepatol · 2010 Score 61

    …biopsy. ### Methods Fifty patients, aged 2 to 18 years, with chronic HCV…

    ActiTest FibroTest HCV

  94. Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.

    Kucharska M et al. · Pol Arch Intern Med · 2017 Score 61

    ### Introduction Hepatitis C virus (HCV) is the major cause of chronic liver…

    FibroTest HCV

  95. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Score 60

    FibroTest Alcohol HBV HCV +3

  96. Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.

    Canbakan M et al. · Nephron Clin Pract · 2011 Score 60

    …Eleven of the 33 patients had scores ≤0.2, 6 had significant…

    FibroTest HCV

  97. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.

    Elalfy MS et al. · Ann Hepatol · 2013 Score 59

    ### Background The main causes of liver fibrosis in transfusion-dependent thalassemia major…

    ActiTest FibroTest HCV

  98. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.

    Laharie D et al. · Eur J Gastroenterol Hepatol · 2010 Score 59

    ### Background The only way to diagnose nodular regenerative hyperplasia (NRH) is liver…

    FibroTest Other

  99. Diagnostic accuracy of the Coopscore© to predict liver fibrosis in human immunodeficiency virus/hepatitis B virus co-infection.

    Taibi L et al. · Ann Clin Biochem · 2018 Score 59

    Background Non-invasive methods for assessing liver fibrosis are increasingly used as…

    FibroTest HBV HIV

  100. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

    Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014 Score 58

    …assessment of AST-ULN in 2 control populations 7521 healthy volunteers and…

    FibroTest Alcohol HBV HCV +1

  101. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.

    Chládek J et al. · J Eur Acad Dermatol Venereol · 2013 Score 58

    …Index PASI 13.5, range 2.2-33) at baseline and weeks…

    FibroTest Other

  102. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.

    Preda CM et al. · Liver Int · 2018 Score 57

    …Serious adverse events related to therapy were reported in 61/2070(2

    FibroTest HCV

  103. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Score 57

    …pre-selected cut-off thresholds; (2) the influence of potential confounding variables…

    FibroTest Alcohol

  104. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Score 56

    ActiTest FibroTest HCV

  105. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2011 Score 56

    ### Background Two widely used biomarkers of fibrosis, FibroTest and liver stiffness measurement…

    FibroTest HCV

  106. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Score 56

    …late-onset LALD came from 2 families, each with a boy (aged…

    FibroTest Metabolic

  107. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Score 55

    ActiTest FibroTest HBV

  108. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Score 55

    ActiTest FibroTest HCV

  109. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Score 54

    ActiTest FibroTest HBV

  110. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Score 54

    This review summarizes the methodological aspects of the interpretation of non-invasive…

    ActiTest FibroTest SteatoTest Alcohol +5

  111. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Score 53

    ### Background Urea cycle disorders (UCDs) are among the most common inborn errors…

    ActiTest FibroTest Other

  112. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference. Key publication

    Peta V et al. · World J Hepatol · 2025 Score 53

    ActiTest FibroTest Autoimmune hepatitis

  113. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.

    Rhodes FA et al. · J Gastroenterol Hepatol · 2021 Score 53

    ### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…

    FibroTest Alcohol

  114. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication

    · 2014 Score 52

    These are the first guidelines dealing with hepatitis C treatment produced by…

    FibroTest HCV

  115. Non-invasive markers for hepatic fibrosis. Review

    Baranova A et al. · BMC Gastroenterol · 2011 Score 52

    With great advancements in the therapeutic modalities used for the treatment of…

    FibroTest Alcohol HBV HCV +3

  116. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Score 51

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  117. Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication

    Score 51

    FibroTest HBV HCV

Affichage de la liste complète des résultats. La page est rendue côté serveur et non paginée.